Description: Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.
Home Page: www.exscientia.ai
EXAI Technical Analysis
The SchrOedinger Building
Oxford,
OX4 4GE
United Kingdom
Phone:
44 18 6581 8941
Officers
| Name | Title |
|---|---|
| Prof. Andrew L. Hopkins DPHIL, FRSE FRSC | Founder, CEO & Exec. Director |
| Mr. Ben Ashwell-Fryer | VP of Fin. |
| Mr. Ben R. Taylor | CFO, Chief Strategy Officer & Exec. Director |
| Ms. Heather Togwell | Operations Mang. |
| Ms. Margo Mosley | VP of Facilities & Operations |
| Dr. Garry Pairaudeau Ph.D. | Chief Technology Officer |
| Dr. David Hallett Ph.D. | Chief Scientific Officer |
| Ms. Eileen Jennings-Brown | Chief Information Officer |
| Ms. Sara Sherman | VP of Investor Relations |
| Mr. Dan Ireland | VP of Legal |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0044 |
| Price-to-Sales TTM: | 23.3243 |
| IPO Date: | 2021-10-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 285 |